| CHRS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CHRS shares outstanding history going back to 11/6/2014:
Also see: CHRS Market Cap History CHRS YTD Return |
CHRS Shares Outstanding History — Coherus BioSciences Share Count Over Time
As of 7/31/2026 Coherus BioSciences has 154.50 million CHRS shares outstanding. Investors often track the CHRS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows CHRS share count trends over time, with 43 historical shares outstanding datapoints presented, dating back to 11/6/2014.
| CHRS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHRS Historical Shares Outstanding: +14.34% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CHRS Stock Price Chart |
| About Coherus Oncology Inc |
| Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the research, development and commercialization of immunotherapies to treat cancer. Co.'s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. We show 43 historical shares outstanding datapoints in our coverage of CHRS's shares outstanding history. Understanding the changing numbers of CHRS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CHRS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CHRS by allowing them to research CHRS shares outstanding history as well as any other stock in our coverage universe. |
| CHRS Current Stock Quote |
Quotes delayed 20 minutes  Free CHRS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| CHRS Share Performance |
| Shares Outstanding Peers |
| Coherus BioSciences (CHRS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
CI Shares Outstanding History CINC Shares Outstanding History CING Shares Outstanding History CIRC Shares Outstanding History CKPT Shares Outstanding History CLBS Shares Outstanding History CLDX Shares Outstanding History CLNN Shares Outstanding History CLOV Shares Outstanding History CLPT Shares Outstanding History More Healthcare companies » |
CHRS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
